

Endologix Investor Relations Department 2 Musick Irvine, CA 92618 United States

Visit IR website ☐ Sign-up for Email alerts ☐

5.00
11:30 AM ET Jun 29, 2017
0.02 🕈 (+0.301%)
4.94 - 5.06
4.21 - 14.50
218,879

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

Addressing a signi... (more)

Stock Performance



Press Releases [View all]

Jun 3, 2017

Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial

May 31, 2017

Endologix Reports Positive Clinical Data from the Ovation LUCY Study

May 17, 2017

Endologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status

May 4, 2017

Endologix Reports First Quarter 2017 Financial Results

Apr 24, 2017

Endologix, Inc. to Host an Investor
Conference Call to Discuss its Nellix®
Endovascular Aneurysm Sealing System
Presentation at the Society of Vascular
Surgery Annual Meeting on June 3, 2017

Financials [View all]

First Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

May 1, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)